Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PI3K-Inhibitor Registry Study: Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

NCT04342117 is registered in ClinicalTrials.gov with SecuraBio as lead sponsor.

NCT NCT04342117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04342117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PI3K-Inhibitor Registry Study: Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
Lead sponsor
SecuraBio
Phase
Observational
Overall status
Terminated
Start date
April 23, 2020
Completion date
December 31, 2020
Enrollment
2 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, follicular lymphoma, lymphoma, lymphoma, non-hodgkin, lymphoma, small lymphocytic